Biome Australia secures supply chain through 2028. The ASX-listed biotechnology company has extended its exclusive supply agreement with Italian partner Probiotical SpA, replacing the previous agreement expiring in June 2026. This extension provides critical continuity as Biome scales internationally across Canada, the United Kingdom, Ireland, and New Zealand. The company reported strong H1 FY2026 results with revenue of $12.4 million and net profit of $1.18 million, achieving positive EBITDA for eight consecutive quarters. Gross margins remain solid at 61.1 percent. Beyond supply security, Biome is advancing its proprietary probiotic strain BMB18 through patent application and human clinical trials with La Trobe University. The company has also reduced debt and shifted to positive operating cash flow, supporting its manufacturing onshoring program and international expansion strategy.
Post from MarketNews_en
Log in to interact with content.